WHO Says AstraZeneca Trial Halt Is 'Good Wake-Up Call'

The video discusses the halting of a clinical trial due to a severe side event, emphasizing the importance of safety in clinical trials. It highlights the ups and downs in research and the need for patience as data is collected from large sample sizes. The timeline for interim results and potential vaccine licensing is outlined, with promising data from phase one and two studies showing immune responses. The video stresses the need for thorough trials to ensure safety and efficacy.

Why was the clinical trial halted according to the first section?

• The vaccine was ineffective

• The trial was completed

• Due to a lack of funding

• Because of a severe side event

What is the primary reason for not rushing clinical trials?

• To wait for more participants

• To save money

• To ensure enough data is collected for safety and efficacy

• To avoid media attention

What is the typical sample size range for current clinical trials?

• 100,000 to 200,000

• 30,000 to 60,000

• 10,000 to 20,000

• 1,000 to 5,000

What kind of immune response have most vaccine candidates shown in phase one and two studies?

• Neutralizing antibodies and sometimes a T cell response

• Only a T cell response

• No response

• Only a B cell response

What is the ultimate goal of conducting large clinical trials for vaccines?

• To shorten the trial duration

• To reduce the cost of vaccines

• To achieve protection from disease, infection, and severe disease

• To increase the stock price of pharmaceutical companies